For The Defense, December 2011 - DRI Today
For The Defense, December 2011 - DRI Today
For The Defense, December 2011 - DRI Today
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>The</strong> “Miranda Warning” of Genetic Mapping—<br />
This Information Can Be Used Against You<br />
<strong>DRI</strong> InTeRnATIonAl<br />
Managing Cross-Border Litigation and Class Actions<br />
Speakers John L. Meltzer of Hogan Lovells LLP (from left),<br />
Timothy Pinos of Cassels Brock & Blackwell LLP, and Gordon<br />
McKee of Blake Cassels & Graydon LLP, provide helpful tips<br />
and suggestions for navigating international litigation in<br />
this Thursday session presented by <strong>DRI</strong> International. <strong>The</strong><br />
panel discussed the need to coordinate efforts, strategies,<br />
and resources in an environment where international<br />
clients are increasingly faced with copy-cat actions arising<br />
from litigation that originated in the United States. Complex<br />
privacy issues, parallel regulatory proceedings, and the<br />
production of documents and information that originated<br />
in countries other than the United States but are sought by<br />
plaintiffs in U.S.-based litigation were also discussed.<br />
DRug AnD MeDICAl DevICe<br />
<strong>The</strong> Legal and the Practical—Updates<br />
on Issues Related<br />
to Preemption and<br />
Sales Representatives<br />
as Witnesses in<br />
Pharmaceutical Cases<br />
Joseph D. Cohen of Porter Hedges LLP<br />
talks to attendees of Thursday afternoon’s<br />
Drug and Medical Device Committee<br />
business meeting and CLE about recent<br />
grants of certiorari by the U.S. Supreme<br />
Court to consider preemption issues<br />
concerning generic manufacturers.<br />
<strong>The</strong> state of the law in this area and the potential ramifications for all<br />
manufacturers were discussed, as well as practical issues related to the role<br />
of sales representatives in pharmaceutical litigation and how to address<br />
plaintiffs’ attempts to portray these individuals and their jobs unfairly.<br />
John M. Conley of Robinson Bradshaw & Hinson<br />
PA speaks during a panel discussion that included<br />
(from left) Bernard Taylor, Sr., of Alston & Bird LLP<br />
(moderator); Misha Angrist, Assistant Professor,<br />
Institute for Genome Sciences and Policy, Duke<br />
University; and Gary E. Marchant, Lincoln Professor<br />
of Emerging Technologies, Law and Ethics,<br />
Sandra Day O’Connor College of Law, Arizona<br />
State University. During this Friday afternoon CLE<br />
presented by the Toxic Torts and Environmental<br />
Law Committee, these leading experts offered<br />
their insights on the potential application of the<br />
genetic revolution and explored the myriad of legal<br />
implications and issues that promise to follow.<br />
eleCTRonIC DIsCoveRy<br />
Backstopping E-Discovery—Drafting<br />
Effective Records Management Policies<br />
Phillip J. Duffy<br />
of Gibbons PC<br />
(seated) and John<br />
J. Jablonski of<br />
Goldberg Segalla<br />
LLP present the<br />
CLE portion of<br />
the Electronic<br />
Discovery<br />
Committee’s<br />
Thursday<br />
afternoon<br />
meeting. During<br />
the program the<br />
two underscored the importance of good records management, the benefits<br />
of having a defensible policy, and some of the key provisions that go into a<br />
well crafted records-management policy.<br />
<strong>For</strong> <strong>The</strong> <strong>Defense</strong> ■ <strong>December</strong> <strong>2011</strong> ■ 21